At CTAD, tau-PET data from people in different stages of various neurodegenerative diseases highlighted both commonalities and peculiarities.
Biogen and Genentech rolled out more data from their Phase 1b trials, renewing hope that amyloid removal will work and shoring up dosing for Phase 3.
Sanofi Genzyme will test a compound currently in development for Gaucher’s disease in Parkinson’s patients who carry a glucocerebrosidase (GBA) mutation.
Cognitively normal people who harbor plaques in their brains are more likely to report feelings of isolation.
Scientists at SfN presented innovative ways to slow amyloid accumulation and preserve synapses.
The tau aggregation inhibitor LMTM tanks in second Phase 3 trial for Alzheimer’s. The sponsor now plans to develop the “placebo.”
CTAD: Solanezumab Seen to Nudge AD Ever so Slightly Tau Inhibitor Fails Again—Subgroup Analysis Irks Clinicians at CTAD Much ‘Adu’ About a Little: Phase 1 Data Feeds the Buzz at CTAD Tau-PET in Down’s: Unique Patterns Among Alzheimer’s Types and Stages ...
Patients on solanezumab saw small improvements on multiple secondary endpoints.
Researchers at SfN 2016 reported that oligomeric and exosomal forms in plasma predict AD as early as a decade prior to symptoms.
Where does TREM2-dependent microglial activity fit into the staging diagram of Alzheimer’s disease?
Despite conflicting results in the past, a large new study analyzing multiple statins in different ethnic groups suggests a protective effect from this class of medication.
Starting next month, Bart de Strooper will head national institute focusing on mechanistic research and evidence-based care.
Researchers at SfN 2016 proposed dialing up the immune response in Alzheimer’s brains to enhance phagocytosis.
At SfN 2016, researchers debuted new mouse models that may better represent human disease.
Researchers at SfN 2016 touted the advantages of APP knock-ins, but noted they are less useful than overexpression models for studying behavior.